UBS AM’s Structure Therapeutics GPCR Stock Holding History

UBS AM’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,170	Closed	-$86.5K	–	2414
2025 Q2	$86.5K	Sell	4,170 -1,745	-30%	-$38.4K	﹤0.01%	2591
2025 Q1	$102K	Buy	+5,915	New	+$145K	﹤0.01%	2599

Other funds holding GPCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM's GPCR Position: Q3 2025 in Review

UBS AM sold out of Structure Therapeutics (GPCR) in Q3 2025, closing a stake of 4,170 shares — an estimated $86.5K sold.

UBS AM first reported a position in GPCR in Q1 2025 and held it in 2 quarters. The position peaked at $102K in Q1 2025. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

UBS AM reported no remaining Structure Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS AM sold 4,170 Structure Therapeutics shares in Q3 2025, an estimated $86.5K.
UBS AM first reported a position in Structure Therapeutics in Q1 2025 and held it in 2 quarters.
UBS AM's Structure Therapeutics position peaked at $102K in Q1 2025.
156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.